RBI
ESPR

Raiffeisen Bank International’s Esperion Therapeutics ESPR Stock Holding History

Raiffeisen Bank International’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,400
Closed -$8.51K – 847
2025
Q2 		$4.33K Hold
4,400
– – ﹤0.01% 563
2025
Q1 		$6.34K Hold
4,400
– – ﹤0.01% 569
2024
Q4 		$9.92K Buy
+4,400
New +$10.3K ﹤0.01% 562

Other funds holding ESPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raiffeisen Bank International's ESPR Position: Q3 2025 in Review

Raiffeisen Bank International sold out of Esperion Therapeutics (ESPR) in Q3 2025, closing a stake of 4,400 shares — an estimated $8.51K sold.

Raiffeisen Bank International first reported a position in ESPR in Q4 2024 and held it in 3 quarters. The position peaked at $9.92K in Q4 2024. 188 funds tracked by Wall St. Rank hold ESPR as of Q3 2025.

  • Raiffeisen Bank International reported no remaining Esperion Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raiffeisen Bank International sold 4,400 Esperion Therapeutics shares in Q3 2025, an estimated $8.51K.
  • Raiffeisen Bank International first reported a position in Esperion Therapeutics in Q4 2024 and held it in 3 quarters.
  • Raiffeisen Bank International's Esperion Therapeutics position peaked at $9.92K in Q4 2024.
  • 188 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2025.

Based on Raiffeisen Bank International's 13F filing for Q3 2025, filed 10 Nov 2025.